#NPCE

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook NeuroPace (Nasdaq: NPCE) reported Q4 2025 revenue of $26.6M (+24% YoY) and full-year 2025 revenue of $100.0M (+25% YoY). RNS System revenue was $22.4M in Q4 and $81.7M for 2025. Gross margin improved to 77.4% in Q4 and 77.2% for the year.The company submitted a PMA supplement for IGE, expects potential mid-2026 approval, received higher Medicare reimbursement rates for implants/replacements, and reiterated 2026 guidance with 20–22% core RNS growth and revenue guidance of $98–$100M.

1 month ago

#NPCE NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

www.stocktitan.net/news/NPCE/neuro-pace-rep...

0 0 0 0

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook Cash equivalents and short-term investments balance as of December 31, 2025 was $61.1 million, a $1.1 million increase compared with $60.0 million at the end of the third quarter 2025.. For full year 2025, total preliminary unaudited revenue is expected to be approximately $100 million, an increase of 25% over 2024. Accordingly, the Company expects to begin...

2 months ago

#NPCE NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

www.stocktitan.net/news/NPCE/neuro-pace-rep...

0 0 0 0

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy NeuroPace (Nasdaq: NPCE) filed a PMA supplement with the U.S. Food and Drug Administration on December 17, 2025, seeking to expand the RNS System indication to antiseizure‑medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic‑clonic (GTC) seizures.The submission is supported by preliminary 18‑month NAUTILUS data showing a 77% median GTC seizure reduction and a favorable safety profile, and the RNS System has received Breakthrough Device Designation for this IGE indication. Under current FDA guidance, PMA supplements are typically reviewed in about 180 days, although actual review times may vary.

3 months ago

#NPCE NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

www.stocktitan.net/news/NPCE/neuro-pace-fil...

0 0 0 0

@smcapstrategist.bsky.social

4 months ago

#NPCE NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

www.stocktitan.net/news/NPCE/neuro-pace-ann...

0 0 0 0

Small Cap Strategist

5 months ago

Trade Alert, Wednesday November 5, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend, Ave Dir Indx, Wed Nov 5th - #HMR #PVBC #OMCL #NPCE #LOCO #HLIT #GDYN #TYG #SD #OOMA #CXW - More: crystalequityresearch.com/trade-alert-... - #smallcap

1 0 0 0

@nasdaq.activitypub.awakari.com.ap.brid.gy

5 months ago

#NPCE NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

www.stocktitan.net/news/NPCE/neuro-pace-rep...

0 0 0 0

VS.Vasiliou

@vsvasiliou.bsky.social

6 months ago

🧠 Presented today at #NPCE on personalised psychological care for youth.
Why it matters:
📱 Therapy that adapts daily
🎯 Goals that evolve with the adolescent
🔄 Real-time nudges = real change
Mental health care is going personal — and digital.

@rhulpsychology.bsky.social @myacbs.bsky.social

1 1 0 0

Nasdaq

7 months ago

NeuroPace Revenue Jumps 22 Percent in Q2 | The Motley Fool

#NPCE #bcefed91-b57b-478f-b2e4-d7815f0b4955 #data-news

Origin | Interest | Match

0 0 0 0

Pomerantz Law Firm Launches Investigation Regarding NeuroPace, Inc. Investor Claims Pomerantz LLP investigates possible securities fraud involving NeuroPace, Inc., following concerning study results and a significant stock price drop.

9 months ago

Pomerantz Law Firm Launches Investigation Regarding NeuroPace, Inc. Investor Claims #USA #New_York #Pomerantz_LLP #NPCE #NeuroPace_Inc

0 0 0 0

NeuroPace Announces Strategic CFO Transition NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has announced a strategic CFO transition. Patrick F. Williams has been appointed as the new Chief Financial Officer effective June 20, 2025, replacing Rebecca Kuhn, who will serve in an advisory role for 12 months.Williams brings over 25 years of financial and operational management experience in public medical device companies, having previously served as CFO at STAAR Surgical, Sientra, and ZELTIQ. The company's RNS System targets a significant market opportunity of approximately 1.2 million U.S. patients living with drug-resistant epilepsy.

9 months ago

#NPCE NeuroPace Announces Strategic CFO Transition

www.stocktitan.net/news/NPCE/neuro-pace-ann...

0 0 0 0

Pomerantz Law Firm Investigates NeuroPace, Inc. for Investor Claims Amidst Stock Drop Pomerantz Law Firm is probing allegations involving NeuroPace, Inc. following a significant stock price drop. Investors are urged to act.

9 months ago

Pomerantz Law Firm Investigates NeuroPace, Inc. for Investor Claims Amidst Stock Drop #USA #New_York #Pomerantz_LLP #NeuroPace #NPCE

0 0 0 0

Pomerantz Law Firm Investigates NeuroPace, Inc. Claims on Behalf of Investors Amid Securities Concerns Pomerantz LLP initiates an investigation into potential securities fraud claims regarding NeuroPace, Inc., following a recent study's disappointing results.

9 months ago

Pomerantz Law Firm Investigates NeuroPace, Inc. Claims on Behalf of Investors Amid Securities Concerns #United_States #New_York #Pomerantz_LLP #NeuroPace #NPCE

0 0 0 0

Pomerantz Law Firm Launches Investigation into NeuroPace, Inc. Investors' Claims Pomerantz LLP is examining claims from NeuroPace investors for potential securities fraud. A significant stock drop followed the company's study results announcement.

10 months ago

Pomerantz Law Firm Launches Investigation into NeuroPace, Inc. Investors' Claims #United_States #New_York #Pomerantz_LLP #NeuroPace #NPCE

0 0 0 0

NeuroPace Secures Up to $75 Million in Debt Financing NeuroPace (NPCE) has secured a new $75 million credit facility with MidCap Financial, comprising a $60 million term loan and a $15 million revolving credit facility. The financing replaces the company's existing term loan with CRG Partners IV and provides working capital for corporate purposes. The new agreement features favorable terms with reduced cash interest expense and a five-year maturity date. Interest rates are set at SOFR (minimum 2%) plus 5.5% for the term loan and 3.75% for the revolving loan. The non-dilutive capital will support NeuroPace's growth initiatives, including expanding access to their RNS System, developing new indications, implementing direct-to-consumer programs, and investing in product development and real-world evidence generation.

10 months ago

#NPCE NeuroPace Secures Up to $75 Million in Debt Financing

www.stocktitan.net/news/NPCE/neuro-pace-sec...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping down in trading, Tue May 27th - #WTO #SGRP #QVCGP #SVRA #RCKT #PRTA #NPCE #MRIN #ZK - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study NeuroPace (NPCE) has announced preliminary one-year results from its NAUTILUS study evaluating the RNS® System for treating drug-resistant idiopathic generalized epilepsy (IGE). The study successfully met its primary 12-week safety endpoint, showing low serious adverse events. While the primary effectiveness endpoint didn't reach statistical significance in the overall population, a significant response was observed in a majority subgroup of patients with lower baseline seizure frequency. The study, involving 87 implanted patients across 23 US epilepsy centers, showed promising median seizure reduction rates exceeding those seen in the company's previous focal epilepsy trials. Notably, patients completing over 12 months showed continued clinical improvement. The company plans to discuss potential regulatory pathways with the FDA, including pursuing a targeted indication for patients with lower baseline seizure frequency.

10 months ago

#NPCE NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

www.stocktitan.net/news/NPCE/neuro-pace-ann...

0 0 0 0

NeuroPace Reports First Quarter 2025 Financial Results -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025

10 months ago

#NPCE NeuroPace Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/NPCE/neuro-pace-rep...

1 0 0 0

US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle US-based manufacturing provides tariff protection for NeuroPace's RNS System. Company reaffirms 2025 margin targets. See full financial implications.

11 months ago

#NPCE NeuroPace Provides Update on Tariff Status

www.stocktitan.net/news/NPCE/neuro-pace-pro...

1 0 0 0

Breakthrough: New Epilepsy Device Shows 82% Seizure Reduction, FDA Study Reveals Landmark FDA study reveals breakthrough efficacy for drug-resistant epilepsy treatment. 324 patients show remarkable seizure reduction. Full analysis inside.

1 year ago

#NPCE NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

www.stocktitan.net/news/NPCE/neuro-pace-ann...

1 0 0 0

Breakthrough Results: NeuroPace's Brain-Responsive Epilepsy Treatment Shows 3-Year Outcomes Latest long-term data reveals effectiveness of first-in-class neuromodulation platform for drug-resistant epilepsy patients. Key findings to be presented at AAN 2025.

1 year ago

#NPCE NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

www.stocktitan.net/news/NPCE/neuro-pace-ann...

0 0 0 0

NeuroPace Strategic Pivot: Higher Margins, AI Innovation, and 20% Growth Target Ahead Strategic portfolio refinement promises 78% margins, AI-enabled products, and expansion into pediatric epilepsy. Company reaffirms 20% revenue growth target. Full analysis inside.

1 year ago

#NPCE NeuroPace Announces Refocusing of Product Portfolio

www.stocktitan.net/news/NPCE/neuro-pace-ann...

0 0 0 0

NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results NeuroPace (NPCE) reported strong Q4 2024 financial results with record quarterly revenue of $21.5 million, up 19% year-over-year. Full-year 2024 revenue increased 22% to $79.9 million.The company completed a public offering of $74.8 million, using $49.5 million to repurchase KCK holdings and $20.2 million to strengthen its balance sheet. Gross margin reached 73.9% in 2024, while operating expenses were $80.8 million.Key developments include:NAUTILUS pivotal study completion expected March 2025Project CARE showing increased implants and referralsNew NEST program using real-world data from 27 pediatric centersDevelopment of AI-enabled software tools and remote programmingFor 2025, NeuroPace projects revenue between $92-96 million, representing 15-20% growth, with gross margin expected between 73-75%.

1 year ago

#NPCE NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/NPCE/neuro-pace-rep...

0 0 0 0

NeuroPace Takes Control: Major Shareholder Exit Signals New Chapter in Growth Strategy Strategic repurchase of KCK's entire stake streamlines ownership structure while public offering proceeds secure operational runway to breakeven

1 year ago

#NPCE NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.

www.stocktitan.net/news/NPCE/neuro-pace-com...

0 0 0 0

NeuroPace Secures Massive $74.8M Capital Injection: Strategic Share Repurchase Unveiled Medical device maker NeuroPace completes $74.8M stock offering at $10/share, plans strategic $49.5M share repurchase from KCK at $9.40/share.

1 year ago

#NPCE NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

www.stocktitan.net/news/NPCE/neuro-pace-ann...

0 0 0 0

NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock NeuroPace (NPCE) has announced the pricing of a public offering of 6.5 million shares of common stock at $10.00 per share, expecting to raise $65 million in gross proceeds. The offering, set to close on February 18, 2025, includes a 30-day option for underwriters to purchase up to 975,000 additional shares.The company plans to use $49.5 million of the net proceeds to repurchase approximately 5.27 million shares from KCK at $9.40 per share. The remaining proceeds will fund general corporate purposes, including clinical trials, R&D expenses, administrative costs, debt reduction, and working capital.The offering is managed by J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners as joint book-running managers, with Lake Street Capital Markets as lead manager.

1 year ago

#NPCE NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock

www.stocktitan.net/news/NPCE/neuro-pace-ann...

0 0 0 0

NeuroPace Unveils Strategic $65M Stock Offering: Major Shareholder Exit & Growth Plans Revealed NeuroPace plans $65M stock offering to repurchase KCK shares, fund clinical trials, and reduce debt. JPMorgan, Cantor lead the underwriting.

1 year ago

#NPCE NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock

www.stocktitan.net/news/NPCE/neuro-pace-ann...

0 0 0 0

NeuroPace's Bold Plan to Transform Epilepsy Treatment: AI, New Markets, and 20% Growth NeuroPace reveals strategic roadmap targeting $96M revenue by 2025, expanding into pediatric epilepsy treatment with AI-powered solutions while pushing for profitability.

1 year ago

#NPCE NeuroPace Issues 2025 Financial Guidance Targets

www.stocktitan.net/news/NPCE/neuro-pace-iss...

0 0 0 0